Saturday, 14 June 2025
  
Login

Australia's most trusted
source of pharma news

Saturday, 14 June 2025
News

FDA win for ex-Novartis exec

Posted 11 June 2025 PM

One of Chimeric Therapeutics’ CAR T therapies has been granted a fast track designation from the FDA, marking the biggest regulatory achievement for the ASX listed company yet.

Led by Novartis Australia’s former Head of Strategic Access, Rebecca McQualter, the Melbourne-based company has two autologous CAR T cell therapies and an allogenic NK cell therapy currently being assessed across multiple different disease areas in oncology with four clinical stage programs.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (15)

Clinical & Medical, R&D (13)

Regulatory, Pharmacovigilance & QA (3)

Devices (1)

Other (16)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.